A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

Clinical trial NCT06313697 · UNKNOWN

Trial details

NCT number: NCT06313697
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infections

Start date: 2024-03-23
Primary completion: 2025-01-06
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.